CLINUVEL Strategic Update – Executive Summary
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read More
Further Research Coverage Initiated on CLINUVEL
CLINUVEL PHARMACEUTICALS LTD today informed its shareholders and interested investors that Jefferies...
Read More
CLINUVEL Annual General Meeting 2020
CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on...
Read More
SCIENTIFIC COMMUNIQUÉ VI
Ultraviolet Radiation Damage and Oxidative Stress in Skin Cancer. October 2020 Introduction...
Read More
CLINUVEL News & Facts site live
Earlier this week CLINUVEL launched a new microsite, CLINUVEL News & Facts. The CLINUVEL...
Read More
Kommuniqué V, 20-23 September 2020
Liebe Aktionäre, Freunde, Während die Welt darum kämpft, die Verbreitung von...
Read More
CLINUVEL Newsletter V
Dear shareholders, friends, As the world battles on to control the...
Read More
CLINUVEL CONFIRMS AGM DATE
Melbourne, Australia, 23 September 2020 CLINUVEL PHARMACEUTICALS LTD today announces it will...
Read More
Opening of VALLAURIX R&D facilities in Singapore
Advanced research facilities to progress pharmaceutical, OTC products EXECUTIVE SUMMARY • CLINUVEL...
Read More
Media Release – CLINUVEL opens VALLAURIX R&D centre in Singapore
The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research&...
Read More
Lapse and Forfeit of Unlisted Conditional Performance Rights
CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and...
Read More
Appendix 4C
CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering...
Read More